Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.4 USD | -0.98% | +7.08% | +44.46% |
May. 10 | Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing | MT |
May. 09 | Crinetics Pharmaceuticals Q1 Net Loss Widens | MT |
Financials (USD)
Sales 2024 * | 2.26M | Sales 2025 * | 17.75M | Capitalization | 4.05B |
---|---|---|---|---|---|
Net income 2024 * | -267M | Net income 2025 * | -294M | EV / Sales 2024 * | 1,467 x |
Net cash position 2024 * | 736M | Net cash position 2025 * | 531M | EV / Sales 2025 * | 198 x |
P/E ratio 2024 * |
-14.5
x | P/E ratio 2025 * |
-13.3
x | Employees | 290 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.01% |
Latest transcript on Crinetics Pharmaceuticals, Inc.
1 day | -0.98% | ||
1 week | +7.08% | ||
Current month | +17.30% | ||
1 month | +19.51% | ||
3 months | +35.91% | ||
6 months | +71.39% | ||
Current year | +44.46% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 07-12-31 |
Scott Struthers
FOU | Founder | 62 | 07-12-31 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 15-09-30 |
Matthew Fust
BRD | Director/Board Member | 59 | 18-01-31 |
Director/Board Member | 71 | 20-09-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.02% | 1,487 M€ | +9.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 51.4 | -0.98% | 635,233 |
24-05-16 | 51.91 | +2.81% | 592,865 |
24-05-15 | 50.49 | +2.25% | 997,957 |
24-05-14 | 49.38 | +3.03% | 540,600 |
24-05-13 | 47.93 | -0.15% | 1,639,626 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.46% | 4.05B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- CRNX Stock